Syngenis Labs: Pioneering Genetic Medicine Commercialization in Australia
Australia is home to numerous talented medical researchers, but there has been a lack of a seamless pathway to commercialize scientific discoveries within the country. Syngenis Labs, a Perth-based biotech company, aims to bridge this gap by raising $4 million to accelerate the development of a business focused on genetic medicine. The company is creating an ecosystem to take RNA and DNA-based medicines from concept to manufacturing under one roof, catering to the growing demand for genetic therapeutics globally.
The success of mRNA vaccines during the COVID-19 pandemic has propelled RNA-based medicine into a rapidly expanding field in healthcare. Syngenis specializes in DNA and RNA assay design and oligonucleotide synthesis, supporting researchers in developing precision medicines and diagnostic tools. By controlling the entire process, the company believes it has a competitive advantage in the market.
Syngenis' proprietary artificial intelligence platform, Discovery AI, plays a crucial role in identifying therapeutic targets, designing candidates, and preparing them for validation. The company's research-grade manufacturing business generates revenue from various clients and is set to expand with the construction of a Good Manufacturing Practice (GMP) facility. This facility will enable Syngenis to manufacture human-grade oligonucleotide products for clinical trials, positioning it as a leader in the field.
In addition to its manufacturing capabilities, Syngenis is developing an AI engine to simulate clinical trials and reduce development costs. The company's diversified approach includes expanding into clinical research services, whole-genome testing, and investment funds to support RNA and DNA projects. By building multiple revenue streams around its technology platform, Syngenis aims to mitigate risks associated with relying on a single drug candidate.
The oversubscribed capital raising has bolstered Syngenis' balance sheet and paved the way for a potential ASX listing. With a focus on maturing each division into a scalable commercial business, the company is poised to play a critical role in advancing Australia's genetic medicine sector. By offering integrated capabilities in a sector where they are scarce, Syngenis is positioning itself as essential infrastructure for the future of genetic medicine.